<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052909</url>
  </required_header>
  <id_info>
    <org_study_id>30286</org_study_id>
    <nct_id>NCT01052909</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this bioequivalence study is to compare a test Glimepiride 1 mg tablets of
      Dr.Reddy's Laboratories Limited versus reference Amaryl 1 mg tablets of Aventis
      Pharmaceuticals Inc in healthy subjects, under fasting condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was Single centre, randomized, single-dose, open-label,2-way crossover,
      bioequivalence study to compare a test Glimepiride 1 mg tablets of Dr.Reddy's Laboratories
      Limited versus Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc in healthy subjects, under
      fasting condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study of Dr. Reddy's Laboratories Limited, Glimepiride tablets 1 mg under Fasting condition</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amaryl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride tablets 1 mg</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Amaryl</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-child-bearing potential female,smoker and or non-smoker,18 years of age
             and older.

          -  Capable of consent.

          -  Non-child-bearing potential female subject:

          -  Post-menopausal state:absence of menses for 12 months prior to drug. administration or
             hysterectomy with bilateral oophorectomy at least 6 months prior to drug
             administration.

          -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6
             months prior to drug administration.

        Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant illnesses &amp; surgery within 4 weeks prior to the administration
             of the study medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which,in the opinion of the Medical Sub-Investigator,would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive testing for hepatitis B and C or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.

          -  BMIâ‰¥30.0.

          -  History of significant alcohol abuse within six months prior to the screening visit or
             any indication of the regular use of more than fourteen units of alcohol per week (l
             Unit=150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months prior to the screening visit or hard drugs (such as cocaine,
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive
             urine drug screen at screening.

          -  History of allergic reactions to glimepiride or other sulfonylureas (e.g.
             chlopropamide,gliclazide, tolbutamide and glyburide).

          -  History of allergic reactions to heparin.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampinlrifabutin;
             examples of inhibitors: antidepressants, cimetidine. diltiazem, erythromycin,
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior
             to administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication. .

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea. inflammatory bowel diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism. or excretion of the drug.

          -  Any clinically significant history or presence of clinically significant
             neurological,endocrinal, cardiovascular, pulmonary, hematologic, immunologic,
             psychiatric, or metabolic disease.

          -  Use of prescription medication (including hormone therapy) within 14 days prior to
             administration of study medication or over-the-counter products (including natural
             food supplements, vitamins, garlic as a supplement) within 7 days prior to
             administration of study medication, except for topical products without systemic
             absorption.

          -  Difficulty to swallow study medication.

          -  Smoking more than 25 cigarettes per day.

          -  Any food allergy, intolerance, restriction or special diet that could, in the opinion
             of the Medical Sub-Investigator. contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood prior to administration of the study medication as follows:

          -  50 mL to 300 mL of whole blood within 30 days,

          -  301 mL to 500 mL of whole blood within 45 days, or

          -  more than 500 mL of whole blood within 56 days prior to drug administration.

          -  Subjects with diabetes (including diabetes mellitus).

          -  Subjects with known serious hepatic impairments.

          -  Subjects with clinically significant presence or history of hypoglycemia.

        Additional exclusion criteria for females only:

          -  Breast-feeding subject.

          -  Positive urine pregnancy test at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>GIV 2KB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice President - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence, Glimepiride, Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

